



Powerful solutions for advanced protection

From surgical preparation to postoperative recovery — Solventum has you covered with comprehensive incision management solutions to help protect the surgical site



Your partner for protection

From surgery to recovery, Solventum offers evidence-based technologies and solutions that support the healing process. 3M™ Ioban™ 2 Antimicrobial Incise Drape provide continuous antimicrobial activity and immobilize bacteria to help reduce surgical site contamination and Solventum™ Prevena™ Therapy helps enhance postoperative recovery while improving efficiency and cost savings.



Protect incisions



Reduce contamination¹

From surgical preparation to postoperative healing

Both Ioban 2 Antimicrobial Incise Drape and Prevena Therapy are evidence supported to help protect the surgical site for optimized healing.^{2,3,4,5}

Solventum offers healthcare providers comprehensive solutions (intra and postoperative) to help reduce the risk of surgical site infections (SSIs) and other complications to help provide the best possible care for your patients.



Creating a physical barrier up to the incision edge, Ioban 2 Antimicrobial Incise Drapes provide continuous antimicrobial activity and immobilize bacteria to reduce the risk of surgical site contamination that may be associated with SSI.



Using Prevena Therapy — closed incision negative pressure therapy (ciNPT) — helps manage the environment of closed incisions in patients at risk for developing postoperative complications.⁶

From surgical preparation

loban 2 Antimicrobial Incise Drape provides continuous broad-spectrum antimicrobial activity


Most surgical site infections (SSI) are caused by the contamination of a surgical incision with microbes from the patient's own body during surgery.^{2,4,5} While skin preps reduce microbes on the skin surface, bacteria in the deeper skin layers will remain. Ex vivo evidence demonstrates that iodine released from loban 2 Antimicrobial Incise Drape has been shown to penetrate the deeper skin layers at concentrations effective against MRSA.⁷

The proof is in the science



A study was conducted to investigate the risk factors associated with wound infection with special reference to the use of loban 2 Antimicrobial Incise Drape.⁸

Results: This retrospective study included 296 patients undergoing high risk liver surgery. Of these patients, 122 were treated using an iodophor skin prep and loban incise drape; the other 174 patients were treated with the iodophor skin prep alone. The SSI rates of patients treated with iodophor skin prep alone was 12.1%. In contrast the SSI rates of patients who were treated with iodophor skin prep and an loban incise drape was 3.1%. This result was statistically significant ($p=0.001$).

Skin prep alone



loban 2 Antimicrobial Incise Drapes⁷



To postoperative healing


Solventum™ Prevena™ Therapy manages the incision in patients at risk of postoperative complications

Prevena Therapy is designed to help protect the surgical incision and has been shown in clinical studies of high-risk patients to decrease the risk of surgical site complications.⁹⁻¹⁸ This can also help to reduce the burden on healthcare facilities through reduced reoperations^{10,13,16} and associated additional costs of treatment.^{17,18}

Supported by evidence-based science

A meta-analysis of 11 RCTs, 7 prospective studies, and 12 retrospective studies with 10,408 patients (2,768 in the Prevena group and 7,640 in the conventional dressings group) assessed the performance of Prevena Therapy vs. conventional dressings across multiple surgical specialties.¹⁹

Results: Using a fixed-effects approach (RCT, observational, colorectal/abdominal, obstetrics, lower extremity, groin/vascular, and cardiac), Prevena Therapy demonstrated a statistically significant reduction in the incidence of surgical site infections relative to traditional dressings.



Subgroup analysis	Studies (n)	Total no. of patients (n)	SSI pooled odds ratio (95% CI)	P
RCT	11	1579	2.7 (2.0-3.6)	<0.00001
Observational	19	8829	3.1 (2.3-4.2)	<0.00001
Colorectal/abdominal	6	857	3.3 (2.0-5.5)	<0.00001
Obstetrics	5	1931	1.7 (1.1-2.8)	0.02
Lower extremity	5	1674	6.4 (2.8-14.5)	<0.0001
Groin/vascular	8	1166	3.1 (2.2-4.4)	<0.00001
Cardiac	4	4068	3.3 (1.5-7.6)	0.004


You're in control

Choosing the right postoperative incision management solution can help to avoid further complications and support your patient on the path to recovery.

To select the right incision management solution for your patient, it is recommended that the following incision and operative risk factors should be assessed alongside the patient's risk factors²⁰:

Does the patient have two or more risk factors?*

- BMI > 35
- Diabetes Mellitus
- Smoker (current)
- Malignancy/ chemotherapy
- Immunodeficiency
- Renal deficiency/ chronic kidney disease
- COPD
- Age >75 years
- Malnourished



Is the procedure high risk?*

- Emergency surgery
- Revision surgery
- Extended surgical time
- Traumatized soft tissue
- Contamination
- High tension incision
- Multiple incisions

*This is not an exhaustive list of risk factors. Clinicians are advised to follow their judgment to identify high risk patients and procedures.

ciNPT = closed incision negative pressure therapy

For more information contact your Solventum representative.

- Payne J. Evaluation of the resistance of the Prevena incision dressing top film to viral penetration. 0000021109, 1-2. 6-19-2009. San Antonio, TX, Kinetic Concepts, Inc.
- NICE (2019) Surgical site infections: prevention and treatment, Clinical guideline [NG125]. Published April 2019.
- RKI (2018) Prevention of postoperative wound infections: Commission recommendation for hospital hygiene and infection prevention (KRINKO) at Robert Koch Institute, Published April 2018.
- Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and prevention Guideline for the Prevention of a Surgical Site Infection, 2017. *JAMA Surg.* 2017 Aug; 152(8):784-791.
- Sterile Technique Guideline. Guidelines for Perioperative Practice. Association of PeriOperative Registered Nurses (AORN). 2021. Accessed 11/29/2021. <https://aornguidelines.org/guidelines/content?sectionid=173717350&view=book#202507982>.
- WHO (2018) Global guidelines for the prevention of surgical site infection, second edition. Geneva: World Health Organization. Published 2018.
- Elliott et al. Antimicrobial activity and skin permeation of iodine present in an iodine-impregnated surgical incise drape. *J. Antimicrobial Chemotherapy.* 2015.
- Yoshimura et al. Plastic iodophor drape during liver surgery operative use of the iodophor impregnated adhesive drape to prevent wound infection during high risk surgery. *World J. Surgery.* 2003; 27:685-688.
- Ferrando PM, Ala A, Bussone R, Bergamasco L, Actis Perinetti F, Malan F. Closed incision negative pressure therapy in oncological breast surgery: comparison with standard care dressings. *Plast Reconstr Surg Glob Open.* 2018 Jun 15;6(6):e1732. doi:10.1097/GOX.0000000000000173.
- Pleger SP, Nink N, Elzien M, Kunold A, Koshty A, Boning A. Reduction of groin wound complications in vascular surgery patients using closed incision negative pressure therapy (ciNPT): a prospective, randomised, single-institution study. *Int Wound J.* 2018;15(1):75-83.
- Cooper HJ, Bas MA. Closed-incision negative-pressure therapy versus antimicrobial dressings after revision hip and knee surgery: a comparative study. *J Arthroplasty.* 2016 May;31(5):1047-1052. doi:10.1016/j.arth.2015.11.010#.
- Redfern RE, Cameron-Ruetz C, O'Drobinak SK, Chen JT, Beer KJ. Closed incision negative pressure therapy effects on postoperative infection and surgical site complication after total hip and knee arthroplasty. *J Arthroplasty.* 2017;32:3333-3339. doi:10.1016/j.arth.2017.06.019.
- Newman JM, Siqueira MBP, Klika AK, Molloy RM, Barsoum WK, Higuera CA. Use of closed incisional negative pressure wound therapy after revision total hip and knee arthroplasty in patients at high risk for infection: a prospective, randomized clinical trial. *J Arthroplasty.* 2019 Mar;34(3):554-559e1. doi:10.1016/j.arth.2018.
- Stannard JP, Volgas DA, McGwin G 3rd, et al. Incisional negative pressure wound therapy after high-risk lower extremity fractures. *J Orthop Trauma.* 2012;26(1):37-42. doi:10.1097/BOT.0b013e318216b1e5.
- Grauhan O, Navasardyan A, Hofmann M, et al. Prevention of poststernotomy wound infections in obese patients by negative pressure wound therapy. *J Thorac Cardiovasc Surg.* 2013;145:1387-1392.
- Gabriel A, Sigalove S, Sigalove N, et al. The impact of closed incision negative pressure therapy on postoperative breast reconstruction outcomes. *Plast Reconstr Surg Glob Open.* 2018 Aug; 6(8):e1880. doi:10.1097/GOX.0000000000001880.
- Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B, Salvatore D, Reiter D, DiMuzio P. A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. *J Vasc Surg.* 2018 Dec;68(6):1744-1752. doi: 10.1016/j.jvs.2018.05.224. Epub 2018 Aug 17. PMID: 30126781.
- Gabriel A, Maxwell GP. Economic Analysis Based on the Use of Closed-Incision Negative-Pressure Therapy after Postoperative Breast Reconstruction. *Plast Reconstr Surg.* 2019 Jan;143(1S) Management of Surgical Incisions Utilizing Closed-Incision Negative-Pressure Therapy):36S-40S. doi: 10.1097/PRS.00000000000005311. PMID: 30586102.
- Singh DP, Gabriel A, Parvizi J, Gardner MJ, D'Agostino R Jr. Meta-Analysis of Comparative Trials Evaluating a Single-Use Closed-Incision Negative-Pressure Therapy System. *Plast Reconstr Surg.* 2019 Jan;143(1S):41S-46S.
- Willy C, Agarwal A, Andersen CA, Santis GD, Gabriel A, Grauhan O, Guerra OM, Lipsky BA, Malas MB, Mathiesen LL, Singh DP et Reddy VS (2017). Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. *Int Wound J.* 14: 385-398.



Solventum Advanced Wound Care
12930 IH20 W
San Antonio, TX 78249
USA

Phone 800-275-4524
Web Solventum.com

The effectiveness of Solventum™ Prevena™ Therapy in reducing the incidence of SSI and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at Solventum.com.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.

© Solventum 2025. Solventum, the S logo and other trademarks are trademarks of Solventum or its affiliates. 3M, the 3M logo and other trademarks are trademarks of 3M. Other trademarks are the property of their respective owners.

70-2013-1333-8